Overview

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Status:
Withdrawn

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to compare the efficacy and safety of exemestane alone or in combination with pazopanib in postmenopausal women who have hormone receptor positive breast cancer and have failed therapy with tamoxifen, anastrazole or letrozole.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Exemestane
Hormones